A5003014678- Lung Cancer Treatments and Mutations
- Cancer Genomics and Diagnostics
- Colorectal Cancer Treatments and Studies
- Genetic factors in colorectal cancer
- HER2/EGFR in Cancer Research
- Gastric Cancer Management and Outcomes
- Cancer Cells and Metastasis
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
- Cancer Treatment and Pharmacology
- Lung Cancer Diagnosis and Treatment
- Pancreatic and Hepatic Oncology Research
- PI3K/AKT/mTOR signaling in cancer
- Cancer-related gene regulation
- Estrogen and related hormone effects
- Bone health and treatments
- Monoclonal and Polyclonal Antibodies Research
- Radiomics and Machine Learning in Medical Imaging
- Hepatocellular Carcinoma Treatment and Prognosis
- RNA modifications and cancer
- Cholangiocarcinoma and Gallbladder Cancer Studies
- TGF-β signaling in diseases
- Neuroendocrine Tumor Research Advances
- PARP inhibition in cancer therapy
- Melanoma and MAPK Pathways
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori
2024-2025
Istituti di Ricovero e Cura a Carattere Scientifico
2013-2025
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"
2015-2024
Cancer Institute (WIA)
2023-2024
National Library of Luxembourg
2024
Tumori Foundation
2024
Azienda Ospedaliero-Universitaria Careggi
2024
University of Florence
2024
University Medical Center Groningen
2022
KU Leuven
2022
•Validated and sensitive ctDNA assays can be used to genotype advanced cancers select patients for targeted therapies.•Initial genotyping with should considered when rapid results are needed, tissue is unavailable.•ctDNA assay limited by false-negative results, lower sensitivity fusion events copy number changes.•Use of detect molecular residual disease not recommended, due lack evidence its clinical utility. Circulating tumour DNA (ctDNA) conducted on plasma rapidly developing a strong base...
Clinical evidence demonstrates that treatment with immune checkpoint inhibitor immunotherapy agents can have considerable benefit across multiple tumours. However, there is a need for the development of predictive biomarkers identify patients who are most likely to respond immunotherapy. Comprehensive characterisation tumours using genomic, transcriptomic, and proteomic approaches continues lead way in advancing precision medicine. Genetic correlates response therapy been known some time,...
IntroductionTo offer patients with EGFR mutation–positive advanced NSCLC appropriate tyrosine kinase inhibitor treatment, mutation testing of tumor samples is required. However, tissue/cytologic are not always available or evaluable. The large, noninterventional diagnostic ASSESS study (NCT01785888) evaluated the utility circulating free tumor-derived DNA (ctDNA) from plasma for testing.MethodsASSESS was conducted in 56 centers (in Europe and Japan). Eligible (with newly diagnosed locally...
Rechallenge therapy with anti-epidermal growth factor receptor (EGFR) drugs has been suggested in patients chemo-refractory RAS wild-type (WT) metastatic colorectal cancer (mCRC) after initial response to anti-EGFR-based first-line treatment. The association of treatment cetuximab plus avelumab overall survival (OS) may be worthy investigation this setting.To assess the efficacy and safety rechallenge avelumab.This single-arm, multicenter phase 2 trial enrolled from August 2018 February...
Advancements in the field of precision medicine have prompted European Society for Medical Oncology (ESMO) Precision Medicine Working Group to update recommendations use tumour next-generation sequencing (NGS) patients with advanced cancers routine practice.